Ultimovacs Receives FDA Orphan Drug Designation for the UV1 Cancer Vaccine for Treatment of Mesothelioma

The orphan drug designation was granted based on data from the randomized Phase II clinical trial NIPU The results from the NIPU study will be presented at the ESMO Congress being held October 20-24, 2023 in MadridUV1 also received FDA orphan drug designation for treatment of patients with malignant melanoma in December 2021 Oslo, October 09, 2023: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, today announced that the

Related Keywords

Norway ,Denmark ,Spain ,Oslo ,Madrid ,Australia ,Sweden ,Germany ,Bristol Myers Squibb ,Astrazeneca ,International Agency For Research On Cancer Globocan ,Halle University ,Oslo University Hospital ,Office Of Orphan Products Developments ,Professor At Oslo University Hospital ,Drug Administration ,Orphan Drug Designation ,Principal Investigator ,Oslo University ,Carlos De Sousa ,Orphan Products Developments ,International Agency ,Human Leukocyte Antigen ,Uv1 ,Mesothelioma ,Cancer Vaccines ,Malignant Melanoma ,Xipu ,Checkpoint Inhibitors ,Phase Ii Clinical Trial ,Dancer ,Fda ,